Publications Using MCE Products

Neurobiol Dis. DOI: 10.1016/j.nbd.2014.08.005. (2014). J Virol. pii: JVI.01867-14. (2014). Chem Biol.18(6):679-80.(2011) Leukemia. doi: 10.1038/leu. (2014) Nat Med. doi: 10.1038/nm.3610 (2014). Nature. doi: 10.1038/nature13485 (2014). Arch Virol. (2014). Spectrochim Acta A Mol Biomol Spectrosc.131:347-54 (2014). Cell Death Dis. 5:e1338.(2014). PLoS One. 9(7):e100985. (2014). Environ Toxicol Pharmacol. (2014). Stem Cell Research (2014). Antimicrob Agents Chemother. pii: AAC.03534-14 (2014). BioMed Research International. (2014). Chem Biol Drug Des. (2014). Sci Rep. 4:5411 (2014). PLoS One. 9(6):e99083 (2014). Chem Res Toxicol.27(6):949-51 (2014). Biochem Biophys Res Commun. pii: S0006-291X(14)00930-9 (2014). DNA Repair (Amst).pii: S1568-7864(14)00121-9 (2014). ACS Nano.8(6):5468-77 (2014). Biomaterials. pii: S0142-9612(14)00440-2 (2014). Eur Urol. pii: S0302-2838(14)00396-0 (2014). Spectrochim Acta A Mol Biomol Spectrosc.131:347-54 (2014). Virology.456-457:300-9 (2014). Trends Pharmacol Sci. pii: S0165-6147(14)00017-0 (2014). Mol Pain.10(1):10 (2014). Ann Hematol.(2014). Biopolymers.101(4):391-7 (2014). BMC Musculoskelet Disord. 15(1):18 (2014). PLoS One. 9(1):e85780 (2014). Cancer Res. 74(1):15-23 (2014). Am J Physiol Lung Cell Mol Physiol.306(2):L207-15 ( 2014). ACS Nano. 24;8(6):5468-77(2014). Pharmacology 85, 365-371 (2010). Cancer research 73, 5206-5217 (2013). Clinical Cancer Research 19, 598-609 (2013). Cancer research 73, 2574-2586 (2013). J Pharm Biomed Anal. 66:232-9.66, 232-239 (2012). Journal of Alzheimer's Disease 21, 1005-1012 (2010). Journal of bioenergetics and biomembranes 44, 155-161 (2012). International immunopharmacology 15, 38-41 (2013). Current Biology 23, 1514-1526 (2013). European journal of pharmacology 663, 74-79 (2011). Cancer research 73, 2574-2586 (2013). Science translational medicine 5, 196ra199-196ra199 (2013). PloS one 8, e56473 (2013). Hypertension 60, 1207-1212 (2012). American Journal of Physiology-Heart and Circulatory Physiology 299, H1309-H1317 (2010). European journal of nuclear medicine and molecular imaging 40, 1739-1747 (2013). J Pharm Pharmacol. 66(4):574-83 (2014). Antiviral Res. 99(1):6-11 (2013). Nat Cell Biol.14(3):295-303 (2012). BMC Biol.8; 11:78 (2013). Biopolymers. 101(4):391-7 (2014).

Customer Reviews

  • New Products

  • 57 New Products Within 30 Days

  • See More >
  • CL-387785
  • "
  • PathWay: Protein Tyrosine Kinase/RTK

    Target: EGFR

    CL-387785(EKI785; WAY-EKI 785) is an irreversible inhibitor of EGFR with IC50 of 370+/-120 pM; is able to overcome resistance caused by the T790M mutation on a functional level.

  • MORE
  • GKT137831
  • "
  • PathWay: Others

    Target: Others

    GKT137831 is a novel and specific dual Nox1/Nox4 inhibitor with Ki of 140±40 nM and 110±30 nM; a potent inhibitor of fibrosis and hepatocyte apoptosis.

  • MORE
  • SA4503
  • "
  • PathWay: GPCR/G protein

    Target: Sigma Receptor

    SA4503(AGY-94806; Cutamesine) is a selective sigma 1 receptor(σ1R) agonist; high affinity for the sigma 1 receptor subtype labeled by (+)-[3H]pentazocine (IC50 = 17.4 +/- 1.9 nM); 100-fold less affinity for the sigma 2 receptor.

  • MORE
  • SA4503 dihydrochlo...
  • "
  • PathWay: GPCR/G protein

    Target: Sigma Receptor

    SA4503 2Hcl(AGY-94806 2Hcl; Cutamesine 2Hcl) is a selective sigma 1 receptor(σ1R) agonist; high affinity for the sigma 1 receptor subtype labeled by (+)-[3H]pentazocine (IC50 = 17.4 +/- 1.9 nM); 100-fold less affinity for the sigma 2 receptor.

  • MORE